Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 24, Number 3—March 2018
Research Letter

Delftia tsuruhatensis, an Emergent Opportunistic Healthcare-Associated Pathogen

Alexandre Ranc1, Grégory Dubourg1, Pierre Edouard Fournier, Didier Raoult, and Florence Fenollar1Comments to Author 
Author affiliations: MEPHI, UMR, IRD, Aix-Marseille Université, Institut Hospitalo-Universitaire Méditerranée Infection, Marseille, France (A. Ranc, G. Dubourg, D. Raoult); VITROME, Institut Hospitalo-Universitaire Méditerranée Infection, Marseille (P.E. Fournier, F. Fenollar)

Main Article

Table

Characteristics of 11 patients with Delftia tsuruhatensis infection, 2 from the literature and 9 from university hospitals in Marseille, France*

Year, patient age, y/sex Underlying conditions Intravascular device Specimen (description) Clinical features; drug regimen ID method; 
ID (score) Amplification of 16 rDNA (similarity) Ref
2010, 53/F
Metastatic breast cancer
Yes
Blood culture
Port-related bacteremia with fever; ceftriaxone
Phenotypic methods; Comamonas testosteroni
D. tsuruhatensis (99%)
(4)
2012, 53/F
Severe pulmonary hypertension
Yes
Blood culture
Catheter-related bacteremia with chills; oral ciprofloxacin
Phenotypic methods; D. acidovorans
D. tsuruhatensis (100%)
(5)
2008, 77/M
Liver cancer, colic adenocarcinoma
Yes
Bronchial aspirate (105 CFU/mL, pure)
Considered by physicians as colonization
Phenotypic methods; D. acidovorans
D. tsuruhatensis (100%)
Marseille hospitals (this study)
2009, 70/F
Unknown
Unknown
Bronchial aspirate (105 CFU/mL, pure)
Not available
MALDI-TOF MS; D. acidovorans (1.968)
D. tsuruhatensis (99.9%)
Marseille hospitals (this study)
2010, 59/F
Alcoholism, chronic end-stage renal failure
Yes
Blood culture
Catheter-related bloodstream infection; piperacillin, tazobactam, gentamycin
Not available
D. tsuruhatensis (99.9%)
Marseille hospitals (this study)
2010, 6/M
Cystic fibrosis
No
Sputum (103 CFU/mL, not pure)
Not available
MALDI-TOF MS; Arthrobacter castelli
D. tsuruhatensis (99.1%)
Marseille hospitals (this study)
2013, 42/M
Homeless, chronic renal failure, alcoholic hepatitis
Yes
Urine (106 CFU/mL, pure)
Not available
MALDI-TOF MS; D. tsuruhatensis (2.19)
D. tsuruhatensis (99.8%)
Marseille hospitals (this study)
2014, 13/F
Liver transplant
Yes
Blood cultures
(N = 2)
Post-transplant fever; piperacillin, tazobactam
Not available
D. tsuruhatensis (99.9%)
Marseille hospitals (this study)
2015, 47/M
Kidney transplant
Yes
Blood culture
Fever
MALDI-TOF MS; D. tsuruhatensis (2.38)
Not performed
Marseille hospitals (this study)
2015, 82/M
Hemodialysis, vascular dementia
Yes
Blood culture 1
Catheter-related bloodstream infection; ceftazidime
MALDI-TOF MS; D. acidovorans (2.02)
D. tsuruhatensis (100%)
Marseille hospitals (this study)
Blood culture 2
MALDI-TOF MS; D. tsuruhatensis (2.21)
D. tsuruhatensis (100%)
2015, <1/F Preterm birth Yes Respiratory sample 1 (107 CFU/mL)
Ventilator-associated pneumonia; ceftazidime, second-line treatment with imipenem and amikacin MALDI-TOF MS; D. tsuruhatensis (2.08)
D. tsuruhatensis (99.9%)
Marseille hospitals (this study)
Respiratory sample 2 (105 CFU/mL) MALDI-TOF MS; D. acidovorans (2.21) D. tsuruhatensis (100%)

*Ref, reference; ID, identification; MALDI-TOF MS, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.

Main Article

1These authors contributed equally to this article.

Page created: February 16, 2018
Page updated: February 16, 2018
Page reviewed: February 16, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external